The traditional view of Alzheimer's as primarily a plaque disease is evolving as evidence mounts that brain inflammation may be the critical accelerant driving cognitive decline. This comprehensive analysis reveals how activated immune cells in the brain—microglia and astrocytes—don't just respond to amyloid-beta deposits but actively worsen the disease cascade, amplifying both plaque formation and tau protein tangles while systematically destroying synaptic connections. The inflammatory response creates a destructive feedback loop where damaged neurons release signals that further activate brain immune cells, perpetuating neurodegeneration long after initial protein misfolding begins. Recent clinical trials with monoclonal antibodies targeting amyloid plaques show modest benefits, with donanemab demonstrating a 60% reduction in cognitive decline rates among patients with mild dementia. However, these therapies primarily address downstream consequences rather than the inflammatory drivers that may be more fundamental to disease progression. The genetic landscape reveals six key mutations affecting amyloid processing and tau stability, but even individuals without high-risk variants can develop significant neuroinflammation through environmental and lifestyle factors. This inflammatory model suggests that future therapeutic strategies should target brain immune dysfunction alongside protein clearance. The implications extend beyond drug development to prevention strategies, as chronic systemic inflammation from poor diet, sedentary lifestyle, and inadequate sleep may prime the brain for Alzheimer's pathology decades before symptoms emerge.